Comparison 1. Oral/topical non‐absorbed antifungal prophylaxis vs placebo or nothing.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Incidence of invasive fungal infection	4		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
1.1 All VLBW infants	4	1800	Risk Ratio (M‐H, Fixed, 95% CI)	0.20 [0.14, 0.27]
1.2 Only ELBW infants	1	349	Risk Ratio (M‐H, Fixed, 95% CI)	0.12 [0.06, 0.26]
2 Mortality	4		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 All VLBW infants	4	1800	Risk Ratio (M‐H, Fixed, 95% CI)	0.87 [0.72, 1.05]
2.2 Only ELBW infants	1	349	Risk Ratio (M‐H, Fixed, 95% CI)	1.07 [0.51, 2.25]
3 Bronchopulmonary dysplasia	1	171	Risk Ratio (M‐H, Fixed, 95% CI)	1.29 [0.67, 2.49]
4 Necrotising enterocolitis	1	185	Risk Ratio (M‐H, Fixed, 95% CI)	0.97 [0.40, 2.33]
5 Retinopathy of prematurity	1	177	Risk Ratio (M‐H, Fixed, 95% CI)	0.62 [0.30, 1.28]
6 Length of stay in NICU (days)	3	833	Mean Difference (IV, Fixed, 95% CI)	‐0.52 [‐4.34, 3.29]